Efficacy Study of COmbination of Edoxaban and Physiotherapy on PRevention and Thrombogenicity of Venous-Thromboembolism in patients after Total Knee Arthroplasty

Efficacy Study of COmbination of Edoxaban and Physiotherapy on PRevention and Thrombogenicity of Venous-Thromboembolism in patients after Total Knee Arthroplasty - Efficacy Study of COmbination of Edoxaban and Physiotherapy on PRevention and Thrombogenicity of Venous-Thromboembolism in patients after Total Knee Arthroplasty(ESCORT-TKA Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020627

Enrollment

Registered

2016-01-20

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee arthrosis

Interventions

edoxaban plus physiotherapy group Oral administration of 30 mg of edoxaban once daily will be initiated from the second day after the TKA. physiotherapy only group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Meet the diagnostic criteria for TKA 2)Aged from 16 to 85 years old 3)Willingness to give written informed consent and willingness to participate in and comply with the study

Exclusion criteria

Exclusion criteria: 1)Emergent operation 2)Serious infection 3)Allergy to study drug 4)Current thrombosis 5)Taking anti-thrombotic agents such as, aspirin, P2Y12 inhibitor, warfarin and non-vitamin K oral anticoagulants (NOACs), etc. 6)Unwilling to give informed consent 7)inappropriate patient

Design outcomes

Primary

Measure	Time frame
Differences in incidence rate of venous thromboembolism 7 days after opetration,and the changes in T-TAS parameters between edoxaban plus physiotherapy group and physiotherapy only group.	—

Secondary

Measure	Time frame
Between edoxaban plus physiotherapy group and physiotherapy only group,differences in incidence rate of perioperative bleeding event and the changes in PT and aPTT function.	—

Countries

Japan

Contacts

Public ContactDaisuke Sueta

Kumamoto University Hospital Department of Cardiovascular Medicine

sueta-d@kumamoto-u.ac.jp+81-96-373-5175

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026